Market Snapshot

Carrier Screening Market Forecast Year:	2022 - 2028
Carrier Screening Market Historical Year:	2016 - 2021
Carrier Screening Market 2021:	USD 2.21 Billion
Carrier Screening Projected Market 2028:	USD 7.56 Billion
Carrier Screening Market CAGR:	17.3%
Fastest Growing Region:	Asia Pacific
Largest Region:	North America

Carrier Screening Market: By Product and Service, Type, Medical Condition, Technology End User, and Region

Market Synopsis

Global Carrier Screening market is valued at USD 2.21 Billion in 2021 and is projected to reach a value of USD 7.56 Billion by 2028 at a CAGR of 17.3% during the forecast period, 2022–2028.

The medical industry has developed rapidly in the past few decades, with scientific discoveries leading to new hypochondriacal illnesses. Most of these are not deadly diseases but are especially frequent among the population between 20 and 50 years old. This is because this group often neglects preventive checks or already display symptoms close to those of a serious illness thus being treated initially under false diagnosis. For example, many people think that any persistent cold symptom should be examined by a physician right away. The large number of diagnosed cases highlights just how important it is that children’s primary care physicians up their game in communicating both the benefits and the risks attendant to Carrier Screening for recessive genetic disorders, including cystic fibrosis (CF).

Recent Development in Carrier Screening is Playing Key Role in Development of Carrier Screening Market

It has been stated many times by different people within the medical field that due to recent developments in the field, carrier testing should become mandatory when couples get married or even much earlier than this point so they can fully understand what risks they could face if they decide to conceive. However, there are still far too many people who are unaware of the benefits to Carrier Screening and how it can be beneficial in avoiding any complications further down the line.

This is also true within certain religious groups where if couples were made aware of the risks that they could face when conceiving or having children then this would make them more likely to go for carrier testing, especially when considering their faith. Due to this fact, there may be an increased demand for pre-conception genetic counseling services and/or Carrier Screening in these communities as well as in families who do not have a history of serious disease but want to ensure they avoid passing on recessive traits which are routinely screened for during pregnancy, such as cystic fibrosis (CF), sickle cell anaemia, thalassaemia, spinal muscular atrophy and Fragile X syndrome. In the UK alone there are around 100 recessive diseases which could be screened for before conception or during early pregnancy to prevent a significant number of miscarriages and stillbirths as well as a large proportion of children being born with a serious health condition which can decrease life expectancy.

Parameter	Details
Market Size Provided for Years	2016-2028
Base Year	2021
Historic Years	2016-2020
Forecast Years	2022-2028
Segments Covered	Type Expanded Carrier Screening Targeted Disease Carrier Screening Technology DNA Sequencing Polymerase Chain Reaction Microarrays Others End User Hospitals & Clinics Reference Laboratories Physician Offices Others Regions North America Europe Asia Pacific Middle East & Africa Latin America
Region & Counties Covered	North America U.S. Canada Mexico Europe U.K France Germany Italy Spain Rest Of Europe Asia Pacific China Japan India South Korea South East Asia Rest Of Asia Pacific Latin America Brazil Argentina Rest Of Latin America Middle East & Africa GCC Cuntries South Africa Rest Of Middle East & Africa
Companies Covered	Invitae (US) Eurofins Scientific (US) Fulgent Genetics (US) OPKO Health (US) Quest Diagnostics (US) Myriad Genetics (US) Sema4 (US) Thermo Fisher Scientific (US) and Illumina (US)
Report Coverage	Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis

Segmentation

The global Carrier Screening market is segmented into type, technology, and end user. On the basis of types the market is segmented into expanded Carrier Screening and targeted disease Carrier Screening. In terms of technology, the market is bifurcated into DNA sequencing, polymerase chain reaction, microarrays, and others. Based on end user the market is segmented into hospitals & clinics, reference laboratories, physician offices, and others.

Expanded Carrier Screening to dominate the Market

Based on Carrier Screening type, the market is segmented into expanded Carrier Screening and targeted disease Carrier Screening. The expanded Carrier Screening holds the major share in the global market owing to advancement in polymerase chain reaction, DNA sequencing, microarrays, and other technologies in Carrier Screening.

The report also states that demand for Carrier Screening is likely to increase markedly as multiplex ligation-dependent probe amplification (MLPA) becomes more widely available to detect large rearrangements associated with hemoglobinopathies such as sickle cell disease, β-thalassemia and α-thalassemia. Currently Carrier Screening is usually performed using biochemical methods which include high performance liquid chromatography (HPLC) or DNA sequencing.

North America and Europe are the Largest Carrier Screening Market

The Carrier Screening market in North America will see a double-digit annual growth over the next few years, largely driven by advances in sequencing technology and growing demand for molecular diagnostics tests. The growth is further supported by increase in Carrier Screening and pre-marital Carrier Screening tests. More than 80% of all carrier testing takes place in Europe, North America, Australia and New Zealand because of the presence of a well-developed healthcare infrastructure with reimbursement for Carrier Screening tests for thalassemia major.

Competitive Landscape

Some of the key players in the global Carrier Screening are Invitae (US), Eurofins Scientific (US), Fulgent Genetics (US), OPKO Health (US), Quest Diagnostics (US), Myriad Genetics (US), Sema4 (US), Thermo Fisher Scientific (US) and Illumina (US), among others.

The Carrier Screening is Segmented as Follows:

• Type
  • Expanded Carrier Screening
  • Targeted Disease Carrier Screening

• Technology
  • DNA Sequencing
  • Polymerase Chain Reaction
  • Microarrays
  • Others

• End User
  • Hospitals & Clinics
  • Reference Laboratories
  • Physician Offices
  • Others

• Regions
  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America